Aravive — Technical Presentation (February 2019)
68 slides from Aravive's technical presentation, Feb 5, 2019
Slide 1: Aravive GAS6/AXL Key Opinion Leader Symposium
Aravive GAS6/AXL Key Opinion Leader Symposium February 5th, 2019 Exhibit 99.1
Slide 2: Important Information: Forward-Looking Statements
Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally i
Slide 3: Agenda
Agenda Welcome - Jay Shepard, CEO History of Axl, Mer and Tyro3 (TAMS) and GAS6/AXL pathway - Greg Lemke, PhD GAS6/AXL Landscape & AVB-S6-500 - Amato Giaccia, PhD, Aravive Co-Founder, Director GAS6/AXL Role in Gynecological Oncology and Other Cancers – Katherine Fuh, PhD, MD AVB-S6-500 Clinical Over
Slide 4: Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway
Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway Greg Lemke, PhD
Slide 5: All the kinases
All the kinases
Slide 6: TAMs among the tyrosine kinases
TAMs among the tyrosine kinases
Slide 7: TAMs and their ligands
TAMs and their ligands cell 2 oy Ca? ions: PtdSer | Gla |Ligand |. ECF) G56 Igt sHac |Pros1 TaM| FN1 Tes FN2 Mer | ™ Tats cell 1
Slide 8: TAM biology
TAM biology invireo Review wicey EEE TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy Yemsratch T.Akalu* | Carla V. Rothlin'? | Sourav Ghosh* REVIEWS I The TAM family: phosphatidylserine- sensing receptor tyrosine kinases gone awry in cancer c
Slide 9: TAM biology cancer virus infection
TAM biology cancer virus infection
Slide 10: TAM biology cancer viral infection vascular biology
TAM biology cancer viral infection vascular biology
Slide 11: TAM biology cancer viral infection vascular biology immune regulation
TAM biology cancer viral infection vascular biology immune regulation
Slide 12: Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway
Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway Greg Lemke, PhD
Slide 13: GAS6/AXL Development Landscape and AVB-S6-500
Amato J. Giaccia, PhD, Aravive Co-founder, Director GAS6/AXL Development Landscape and AVB-S6-500
Slide 14: GAS6/AXL: Multiple Clinical Applications
GAS6/AXL: Multiple Clinical Applications
Slide 15: Few Drugs Specifically Target the Metastatic Tumor In Its Microenvironment
Few Drugs Specifically Target the Metastatic Tumor In Its Microenvironment 6 Source: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology Tumor micro environment drugs include anti-angiogenic agents Avastin and Zaltrap Metastatic Disease Remains The Largest &
Slide 16: Attributes of Key Microenvironment Factor Pathways
Attributes of Key Microenvironment Factor Pathways VEGF/VEGFR signaling: VEGF source: tumor cells, fibroblasts, and macrophages angiogenesis, vasculogenesis, and lymphangiogenesis Approved drugs: bevacizumab, sunitinib, sorafinib, pegaptinib, ranibizumab, ramucirumab PDL-1/PDL-1 signaling: PDL-1 sou
Slide 17: GAS6/AXL Target Rationale
Survival & Proliferation Single agent anti-tumor activity Epithelial-Mesenchymal Transition Tumor Adaptation Mechanism EMT is natural cellular survival program that is harnessed by cancer cells in response to a hostile tumor microenvironment with critical role in several aspects of tumor biology Reg
Slide 18: GAS6/AXL Signaling: A Compelling Anticancer Target
GAS6/AXL Signaling: A Compelling Anticancer Target Activated In Many Different Human Tumors Examples AXL/GAS6 Up-Regulation References AML, CML* >35% Rochlitz et al., 1999 Gioia et al., 2011 Pancreas* 50-70% Song et al., 2011 Koorstra et al., 2009 Ovarian* 50-90% Rankin et al., 2010 Sun et al., 2004
Slide 19: Therapeutic Approaches to Targeting AXL/GAS6
Therapeutic Approaches to Targeting AXL/GAS6 Small Molecule against AXL Pros: direct anti-tumor activity, known chemistry (kinase inhibitors) Cons: selectivity/specificity challenge due to high kinase homology, off target DLT’s, high attrition for SM development, potential for multiple resistance me
Slide 20: Small molecule drugs with AXL inhibitory activity
Small molecule drugs with AXL inhibitory activity Cabozantinib (Exelixis) c-Met, VEGFR2, AXL, Ret, Kit, Flt-1/3/4, Tie2 Approved for medullary thyroid and renal cancer NSCLC, bladder, pancreatic neuroendocrine, endometrial, GIST, breast, sarcomas, CRC, HCC (phases 1-3) BGB324 (BerGenBio) AXL, Abl, M
Slide 21: Receptor Antibodies And Antibody-drug Conjugates Targeting GAS6/AXL
Receptor Antibodies And Antibody-drug Conjugates Targeting GAS6/AXL Compound Sponsor/developer Mechanism YW327.6S2 Genentech Binds to AXL, downregulating AXL expression, inhibiting activation, signalling, and Gas6-dependent Baf3-AXL cell proliferation Anti-AXL D9 and E8 Institut de Recherche en Canc
Slide 22: AVB-S6-500: A Highly Potent Well Characterized Development Candidate
AVB-S6-500: A Highly Potent Well Characterized Development Candidate Soluble hAXL receptor fused to hIgG1 Fc Clinically validated approach to achieve good PK properties and to reduce clinical/regulatory risk Fc portion same as on marketed drugs (e.g. Zaltrap, Orencia) Human fusion protein to avoid i
Slide 23: AVB-S6-500 MOA: Prevents Binding of GAS6 to AXL
Nature Chemical Biology, Kariolis, et. al. Natural Affinity: > 30 pM AVB-S6-500 MOA: Prevents Binding of GAS6 to AXL on Cell Membrane and Blocks AXL Signaling GAS6 Axl Aravive-S6 decoy pAXL Aravive-S6 Affinity: < 0.15 pM
Slide 24: AXL Inhibition by AVB-S6-500 is Selective and Potent in Preclinical Studies
AXL Inhibition by AVB-S6-500 is Selective and Potent in Preclinical Studies AVB-S6-500 BGB324 Foretinib In vivo activity Breast cancer lung metastasis AVB-S6 Radiance [x106] (p/sec/cm2/sr) J Clin Invest. 2017;127(1):183–198
Slide 25: Efficacy - Affinity Matters
*Established Metastatic Disease **Methods in Rankin et al 2012 Methodology for Ovarian Tumor Model with Established Metastatic Disease** Unpublished “Affinity Matters” Efficacy - Affinity Matters
Slide 26: Potential for Complementary or Companion Diagnostic: A Proprietary Biomarker Assay
Potential for Complementary or Companion Diagnostic: A Proprietary Biomarker Assay (1) the ability to measure free Gas6 as a proxy of drug activity in the clinical setting (2) The potential to pre-screen for responder populations to improve chances of success (both in oncology and non-oncology clini
Slide 27: Differentiation & Key Advantages of Targeting AXL Signaling Through GAS6 Inactivation
Differentiation & Key Advantages of Targeting AXL Signaling Through GAS6 Inactivation with Aravive-S6 Improved specificity over small molecule RTK inhibitors RTKs have difficulty obtaining specificity because of kinase homology Multi-kinase inhibitors tend to have exposure limiting side-effects SM m
Slide 28: GAS6 Within the Tumor Microenvironment and Fibrotic Tissue
GAS6 Within the Tumor Microenvironment and Fibrotic Tissue
Slide 29: GAS6/AXL Stimulates Cancer Growth, Survival and Metastasis: A Key EMT Regulator
GAS6/AXL Stimulates Cancer Growth, Survival and Metastasis: A Key EMT Regulator
Slide 30: GAS6/AXL Development Landscape and AVB-S6-500
Amato J. Giaccia, PhD, Aravive Co-founder, Director GAS6/AXL Development Landscape and AVB-S6-500
Slide 31: GAS6/AXL Role in Gynecological Oncology and Other Cancers
GAS6/AXL Role in Gynecological Oncology and Other Cancers Katherine Fuh, MD, PhD
Slide 32: How AXL is Important in Cancer
How AXL is Important in Cancer CANCER IS METASTATIC RELAPSES CHEMORESISTANT NEED TREATMENT THAT ATTACKS ALL THESE STEPS
Slide 33: AXL Is Critical in Renal Cell, Breast, and Liver Cancer Metastasis
AXL Is Critical in Renal Cell, Breast, and Liver Cancer Metastasis
Slide 34: AXL Is Critical in Ovarian and Uterine Cancer Metastasis
AXL Is Critical in Ovarian and Uterine Cancer Metastasis
Slide 35: AXL Regulates Treatment Resistance in Ovarian, Uterine, Renal Cell and Lung Cancer
AXL Regulates Treatment Resistance in Ovarian, Uterine, Renal Cell and Lung Cancer
Slide 36: Original articles on AXL and resistance to therapy
ORIGINAL ARTICLE Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma L Zhou', X-D Liu', M Sun’, X Zhang’, P German’, S Bai’, Z Ding’, N Tannir', CG Wood?, SF Matin?, JA Karam?, P Tamboli®, K Sircar?, P Rao®, EB Rankin‘, DA Laird®, AG Hoang’, CL Walker®, AJ Giaccia
Slide 37: Treatment Paradigm for Ovarian Cancer
Treatment Paradigm for Ovarian Cancer Progression Secondary Diagnosis surgery? ! Chemo ' Chemo Chemo Chemo | Symptoms — #1 -F Maintenance A, = — a2 cee) iia: | C it Death joncomitant \4 Supportive / Staging/debulking care
Slide 38: Need: Anti-metastasis agent and chemotherapy-sensitizing agent
Need: 1) Anti-metastasis agent 2) Chemotherapy-sensitizing agent
Slide 39: AXL is increased post-chemotherapy in tumors that did not respond
Post-chemotherapy - Biopsy Pre-chemotherapy Biopsy NED NED NED DOD AXL is increased post-chemotherapy in tumors that did not respond
Slide 40: Elevated tumor GAS6 and AXL in chemoresistant ovarian cancer
Elevated tumor GAS6 and AXL in chemoresistant ovarian cancer AXL GAS6
Slide 41: Elevated serum GAS6 in chemoresistant ovarian cancer
Elevated serum GAS6 in chemoresistant ovarian cancer
Slide 42: AXL expression correlates with chemoresistance to carboplatin and paclitaxel
AXL expression correlates with chemoresistance to carboplatin and paclitaxel
Slide 43: AVB-S6-500 in combination with chemotherapy prevents cell growth
AVB-S6-500 in combination with chemotherapy prevents cell growth
Slide 44: AVB-S6-500 in combination with chemo inhibits tumor growth
AVB-S6-500 in combination with chemo inhibits tumor growth PDX model OVCAR8 model
Slide 45: Maintenance AVB-S6-500 continues to maintain low tumor volume
Maintenance AVB-S6-500 continues to maintain low tumor volume
Slide 46: AXL is highly expressed in ovarian cancer
AXL is highly expressed in ovarian cancer No Expression Low Moderate - High Total specimens Normal ovary n=10 (100%) n=10 High-grade serous ovarian n=14 (9%) n=6 (4%) n=139 (87%) n=159 Omentum n=3 (9%) n=5 (16%) n=24 (75%) n=32 Peritoneum 1 (3%) 2 (7%) 27 (90%) n=30
Slide 47: GAS6/AXL Role in Gynecological Oncology and Other Cancers
GAS6/AXL Role in Gynecological Oncology and Other Cancers Katherine Fuh, MD, PhD
Slide 48: AVB-S6-500 in IgA Nephropathy
AVB-S6-500 in IgA Nephropathy Gail McIntyre, PhD, DABT Aravive SVP R&D
Slide 49: IgA Nephropathy: Potentially Accelerated Development Pathway
IgA Nephropathy: Potentially Accelerated Development Pathway Most common cause of Primary Glomerulonephritis and responsible for 10% of patients on dialysis Approximately 150,000-180,000 people in the US IgAN is caused by IgA deposits in the kidneys, causing mesangial proliferation (proteinuria) and
Slide 50: Decreased Proteinuria Improves Survival in IgAN
Decreased Proteinuria Improves Survival in IgAN Proteinuria in IgAN patients is associated with renal outcomes and the degree of proteinuria is the best predictor of renal risk 28 Effect of Proteinuria on Renal Survival in IgA Nephropathy Survival from renal failure <0.3 g/day 0.3-1g/day 1-2 g/day 2
Slide 51: GAS6 is expressed in IgAN
GAS6 is expressed in IgAN Control (6 cases) Epithelial type (28 cases) Endo/mes type (3 cases) a - ’ . y A B Cc § : Figure 1. in human IgA th . p with anti shown in (A) (6) from | ar tally and (0 from | ion nephropathy cases mnmunostained in endothellal and mesangial cells The original magnification
Slide 52: GAS6 Expression Correlates with Severity of IgA Nephropathy
GAS6 Expression Correlates with Severity of IgA Nephropathy
Slide 53: Aravive Data: Serum GAS6 Elevated in IgA Patients
Aravive Data: Serum GAS6 Elevated in IgA Patients
Slide 54: Lower Affinity GAS6-trap Improves Fibrosis and Proteinuria in Preclinical Glomerulonephritis
Lower Affinity GAS6-trap Improves Fibrosis and Proteinurea in Preclinical Experimental Glomerulonephritis
Slide 55: High Level Development Plan
High Level Development Plan Small (N of 10-12) IgAN patients treated for 2 mos (4 doses) Open-label Monitor safety, PK/PD Ensure sGAS6 levels suppressed over dosing interval Monitor proteinuria, hematuria and other renal functions Biopsy prior and after treatment to assess effect on renal tissue and
Slide 56: AVB-S6-500 in IgA Nephropathy
AVB-S6-500 in IgA Nephropathy Gail McIntyre, PhD, DABT Aravive SVP R&D
Slide 57: Aravive Clinical Development Program
Aravive Clinical Development Program Gail McIntyre, PhD, DABT Aravive SVP R&D
Slide 58: Why Platinum-Resistant Ovarian Cancer as First Indication?
Why Platinum-Resistant Ovarian Cancer as First Indication? Wealth of preclinical data with AVB-S6-500 in platinum resistant ovarian cancer Platinum-resistant ovarian tumors are highly AXL positive High unmet medical need mPFS for platinum resistant patients given paclitaxel or doxil is 3mos with OS
Slide 59: First Clinical Study in Healthy Volunteers
First Clinical Study in Healthy Volunteers Identified Well-Tolerated and Pharmacologically Active Doses 1 mg/kg 2.5 mg/kg 5 mg/kg 10 mg/kg 5 mg/kg weekly x 4 weeks Single Ascending IV Dose Portion Single-blind, Randomized 6 active/2 placebo per dose Repeat IV Dose Portion Single-blind, Randomized 7
Slide 60: All Doses of AVB-S6-500 Were Well-Tolerated
All Doses of AVB-S6-500 Were Well-Tolerated AVB-S6-500 was well-tolerated across all doses (1-10mg/kg single doses and 4 weekly 5mg/kg doses) Treatment-emergent adverse events generally mild, transient and self-limiting No serious adverse events reported No anti-drug antibodies noted
Slide 61: Proof of Mechanism Demonstrated At All Doses
Proof of Mechanism Demonstrated At All Doses Increased AVB-S6-500 Dose Increased Duration of Abrogation of Serum GAS6
Slide 62: Platinum Resistant Ovarian Cancer Phase 1b/2: Phase 1b Portion
Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 1b Portion Safety lead-in portion of the Phase 1b/2 trial is designed to confirm dose predicted based on Phase 1 study in healthy volunteers Primary objective to assess safety and tolerability; Secondary objective to assess PK/PD and
Slide 63: Platinum Resistant Ovarian Cancer Phase 1b/2: Phase 2 Portion
Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 2 Portion Anticipated Phase 2 Trial Design Status: FPI expected 2H19, topline data expected end of 2020 Total N = 120 Platinum Resistant Ovarian Cancer 1-3 prior lines AVB-S6-500 + Pac N = 40 AVB-S6-500 + PLD N = 40 Pac N = 20 PLD N =
Slide 64: Next Oncology Study: Clear Cell Renal Cell Carcinoma (ccRCC)
Next Oncology Study: Clear Cell Renal Cell Carcinoma (ccRCC) Unmet medical need Kidney cancer is a leading cause of cancer-related deaths in the United States. Metastasis to distant organs including the lung, bone, liver, and brain is the primary cause of death in kidney cancer patients, as only 12%
Slide 65: Rationale for AVB-S6-500 as Treatment for ccRCC
Rationale for AVB-S6-500 as Treatment for ccRCC AXL is increased and activated in response to low oxygen tensions AXL mediates prometastatic behavior in renal cell carcinoma and hepatocellular carcinoma cells under certain conditions AXL plays an important role in both EMT. Inhibition of AXL reverse
Slide 66: Aravive Clinical Development Program
Aravive Clinical Development Program Gail McIntyre, PhD, DABT Aravive SVP R&D
Slide 67: Q&A?
¢°3 aravive Q&A?
Slide 68: Thank you
¢°3 aravive Thank you